Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Promis Neurosciences (PMN) had Cash Flow from Financial Activities of $20.94M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-11.58M |
|
-- |
|
-- |
|
$11.75M |
|
$-11.75M |
|
$0.17M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.58M |
|
$-11.75M |
|
$-11.75M |
|
48.83M |
|
48.83M |
|
$-0.24 |
|
$-0.24 |
|
| Balance Sheet Financials | |
$21.46M |
|
-- |
|
-- |
|
$21.46M |
|
$12.21M |
|
-- |
|
$0.06M |
|
$12.27M |
|
$9.19M |
|
$9.19M |
|
$9.19M |
|
53.81M |
|
| Cash Flow Statement Financials | |
$-18.84M |
|
-- |
|
|
Cash Flow from Financial Activities |
$20.94M |
$13.29M |
|
$15.40M |
|
$2.11M |
|
$0.65M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.76 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-18.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-126.04% |
|
-126.04% |
|
-53.97% |
|
-126.04% |
|
$0.17 |
|
$-0.39 |
|
$-0.39 |
|